BMC Research Notes · 2014 · 15 citations · 16 references
Life SciencesMolecular BiologyMolecular GeneticsCancer GeneticsHuman GeneticsMedical GeneticsCancer Molecular PathologyGenetic DisordersHereditary Cancer SyndromesKidney CancerRenal Cell CarcinomaUterine LeiomyomaFamilial Cancer SyndromesFamilial Renal Cell CarcinomaFumarate Hydratase DeficiencyHereditary LeiomyomatosisHereditary Renal Cell CancerHereditary Renal Cell CarcinomaHereditary Renal Tumor SyndromesPoint Mutation Analysis
BACKGROUND: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare tumor predisposition syndrome characterized by cutaneous and uterine leiomyomas and papillary type 2 renal cell cancer. Germline mutation of the fumarate hydratase (FH) gene is known to be associated with HLRCC. CASE PRESENTATION: We describe a 64-year-old father and his 39-year-old son with HLRCC who developed papillary type 2 RCCs lacking cutaneous leiomyomas at any site. A common missense mutation in the FH gene, (c.1021G > A, p.D341N) in exon 7, was detected in the 2 cases. Functional prediction with the bioinformatics programs, SIFT and Polyphen-2, reported "damaging (SIFT score 0.00)" and "probably damaging (PSIC score 1.621)" values, respectively. In 162 healthy individuals, there were no cases of a G transition to any base. Finally, (c.1021G > A) in exon 7, was identified as a point mutation. CONCLUSION: We report a family with HLRCC in which a novel missense mutation was detected. A familial papillary type 2 renal cancer should be considered HLRCC unless typical cutaneous leiomyomas do not occur.
16